Abbott, the parent company of Madison’s Exact Sciences, announced Tuesday that the Cologuard Plus test has reached an important milestone on the way toward making the noninvasive colorectal cancer screening test available in Europe.
Cologuard Plus, which was developed by Exact Sciences before the company was purchased by Abbott, received CE Mark under the European Union’s In Vitro Diagnostic Medical Devices Regulation as it prepares to introduce Cologuard Plus in European markets.
Abbott is scheduled to release its third-quarter 2026 financial results on Wednesday before the market opens.
